These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 35582961)
1. New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study. Wang HY; Dou KF; Guan C; Xie L; Huang Y; Zhang R; Yang W; Wu Y; Yang Y; Qiao S; Gao R; Xu B Circ Cardiovasc Interv; 2022 Jun; 15(6):e011536. PubMed ID: 35582961 [TBL] [Abstract][Full Text] [Related]
2. Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. Brener SJ; Kirtane AJ; Rinaldi MJ; Stuckey TD; Witzenbichler B; Weisz G; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Brodie BR; Mehran R; McAndrew T; Stone GW Circ Cardiovasc Interv; 2018 Oct; 11(10):e006853. PubMed ID: 30354629 [TBL] [Abstract][Full Text] [Related]
3. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. Gargiulo G; Ariotti S; Santucci A; Piccolo R; Baldo A; Franzone A; Magnani G; Marino M; Esposito G; Windecker S; Valgimigli M JACC Cardiovasc Interv; 2016 Sep; 9(17):1780-9. PubMed ID: 27544007 [TBL] [Abstract][Full Text] [Related]
4. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. Wu H; Xu L; Zhao X; Zhang H; Cheng K; Wang X; Chen M; Li G; Huang J; Lan J; Wei G; Zhang C; Wang Y; Qian J; Ge J; Circulation; 2023 Jan; 147(3):212-222. PubMed ID: 36335890 [TBL] [Abstract][Full Text] [Related]
5. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel). Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840 [TBL] [Abstract][Full Text] [Related]
6. Novel insights on dual antiplatelet therapy duration following stenting for angiography-detected moderate-to-severe calcified coronary lesions. Lin Z; Yuan S; He J; Song Y; Zhang W; Dou K Pharmacol Res; 2024 Oct; 208():107378. PubMed ID: 39216842 [TBL] [Abstract][Full Text] [Related]
7. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. Secemsky EA; Yeh RW; Kereiakes DJ; Cutlip DE; Steg PG; Massaro JM; Apruzzese PK; Mauri L; JACC Cardiovasc Interv; 2017 May; 10(9):942-954. PubMed ID: 28473118 [TBL] [Abstract][Full Text] [Related]
8. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA; 2019 Jun; 321(24):2414-2427. PubMed ID: 31237644 [TBL] [Abstract][Full Text] [Related]
9. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Yeh RW; Kereiakes DJ; Steg PG; Cutlip DE; Croce KJ; Massaro JM; Mauri L; J Am Coll Cardiol; 2017 Oct; 70(18):2213-2223. PubMed ID: 29073947 [TBL] [Abstract][Full Text] [Related]
10. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention. Yamamoto K; Watanabe H; Morimoto T; Obayashi Y; Natsuaki M; Yamaji K; Domei T; Ogita M; Ohya M; Tatsushima S; Suzuki H; Tada T; Ishii M; Nikaido A; Watanabe N; Fujii S; Mori H; Nishikura T; Suematsu N; Hayashi F; Komiyama K; Shigematsu T; Isawa T; Suwa S; Ando K; Kimura T; JACC Cardiovasc Interv; 2023 Jan; 16(1):19-31. PubMed ID: 36599584 [TBL] [Abstract][Full Text] [Related]
11. Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total Cohort. Obayashi Y; Watanabe H; Morimoto T; Yamamoto K; Natsuaki M; Domei T; Yamaji K; Suwa S; Isawa T; Watanabe H; Yoshida R; Sakamoto H; Akao M; Hata Y; Morishima I; Tokuyama H; Yagi M; Suzuki H; Wakabayashi K; Suematsu N; Inada T; Tamura T; Okayama H; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; Circ Cardiovasc Interv; 2022 Aug; 15(8):e012004. PubMed ID: 35912647 [TBL] [Abstract][Full Text] [Related]
12. Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. D'Ascenzo F; Bertaina M; Fioravanti F; Bongiovanni F; Raposeiras-Roubin S; Abu-Assi E; Kinnaird T; Ariza-Solé A; Manzano-Fernández S; Templin C; Velicki L; Xanthopoulou I; Cerrato E; Rognoni A; Boccuzzi G; Omedè P; Montabone A; Taha S; Durante A; Gili S; Magnani G; Autelli M; Grosso A; Blanco PF; Garay A; Quadri G; Varbella F; Queija BC; Paz RC; Fernández MC; Pousa IM; Gallo D; Morbiducci U; Dominguez-Rodriguez A; Valdés M; Cequier A; Alexopoulos D; Iñiguez-Romo A; Gaita F; Rinaldi M; Lüscher TF Eur J Prev Cardiol; 2020 May; 27(7):696-705. PubMed ID: 30862233 [TBL] [Abstract][Full Text] [Related]
13. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662 [TBL] [Abstract][Full Text] [Related]
14. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Natsuaki M; Watanabe H; Morimoto T; Yamamoto K; Obayashi Y; Nishikawa R; Ando K; Domei T; Suwa S; Ogita M; Isawa T; Takenaka H; Yamamoto T; Ishikawa T; Hisauchi I; Wakabayashi K; Onishi Y; Hibi K; Kawai K; Yoshida R; Suzuki H; Nakazawa G; Kusuyama T; Morishima I; Ono K; Kimura T Circulation; 2024 Feb; 149(8):585-600. PubMed ID: 37994553 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome: The STOPDAPT-2 ACS Randomized Clinical Trial. Watanabe H; Morimoto T; Natsuaki M; Yamamoto K; Obayashi Y; Ogita M; Suwa S; Isawa T; Domei T; Yamaji K; Tatsushima S; Watanabe H; Ohya M; Tokuyama H; Tada T; Sakamoto H; Mori H; Suzuki H; Nishikura T; Wakabayashi K; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Morino Y; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; JAMA Cardiol; 2022 Apr; 7(4):407-417. PubMed ID: 35234821 [TBL] [Abstract][Full Text] [Related]
16. Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention. Wang HY; Dou KF; Yin D; Xu B; Zhang D; Gao RL Am J Cardiol; 2020 Oct; 133():61-70. PubMed ID: 32811654 [TBL] [Abstract][Full Text] [Related]
17. Clinical Usefulness of PRECISE-DAPT Score for Predicting Bleeding Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: An Analysis From the SMART-DATE Randomized Trial. Choi KH; Song YB; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Oh JH; Cho DK; Lee JB; Doh JH; Kim SH; Jeong JO; Bae JH; Kim BO; Cho JH; Suh IW; Kim DI; Park HK; Park JS; Choi WG; Lee WS; Gwon HC; Hahn JY Circ Cardiovasc Interv; 2020 May; 13(5):e008530. PubMed ID: 32354228 [TBL] [Abstract][Full Text] [Related]
18. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H; JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838 [TBL] [Abstract][Full Text] [Related]
19. Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network meta-analysis of randomized trials. Shoji S; Kuno T; Ueyama H; Takagi H; Briasoulis A; Kim HS; Koo BK; Kang J; Watanabe H; Kimura T; Kohsaka S J Cardiol; 2024 May; 83(5):338-347. PubMed ID: 37562542 [TBL] [Abstract][Full Text] [Related]
20. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. Costa F; Vranckx P; Leonardi S; Moscarella E; Ando G; Calabro P; Oreto G; Zijlstra F; Valgimigli M Eur Heart J; 2015 May; 36(20):1242-51. PubMed ID: 25718355 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]